ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1282

Classification of Disease Activity and Damage in Cutaneous Lupus

Laila Abbas, Karabi Nandy and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX

Meeting: ACR Convergence 2021

Keywords: Cutaneous, Dermatology, Disease Activity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: The Cutaneous Lupus Disease Area and Severity Index (CLASI) can quantify disease activity and damage in Cutaneous Lupus Erythematosus (CLE). Classification of CLASI scores provides standardized clinical context for patients and providers. A prior study used a small patient cohort to classify CLASI activity (CLASI-A) scores into mild, moderate and severe categories, but was limited by small sample size.1 The objectives of the present study were to classify both CLASI-A and CLASI damage (CLASI-D) scores into mild, moderate, and severe categories using a large, heterogeneous cohort of CLE patients, and determine risk factors for different categories of activity and damage.

Methods: This was a single-center, cross-sectional study involving patients seen in the outpatient dermatology clinics at University of Texas Southwestern and Parkland Health and Hospital System from April 2009 to January 2020. Table 1 shows demographic and clinical features of participants. Skin severity measurements including CLASI and Physicians’ Global Assessment (PGA) of Activity and Damage were scored for all patients. The anchoring outcome measure was the PGA-A and PGA-D, which classified patients into mild, moderate, and severe categories for subsequent analysis with CLASI scores. Severity strata were evaluated using receiver operating characteristics (ROC) curves. Skindex-29+3 scores were collected to evaluate patient quality of life.

Results: 270 patients with CLE (Table 1) met recruitment criteria. CLASI-A scores of 0-6, 7-14, and 15-70 corresponded to mild, moderate, and severe disease activity. These performed better than previously published strata1 by sensitivity, specificity, and percent correctly classified (Table 2). CLASI-D scores of 0-5, 6-16, and 17-56 corresponded to mild, moderate, and severe disease damage. Patients had significantly more impaired quality of life with more severe categories of both activity and damage (p< 0.0001). About half (55%) of patients had matching disease activity and damage categories, with the other half having discrepant categories. Smoking (p=0.002), race (p< 0.0001), CLE subtype (p< 0.0001), and disease duration (p=0.02) were factors that were significantly different amongst the groups of activity and damage (Figure 1). Black race, chronic CLE, and longer disease duration were associated with disease damage disproportionately worse than disease activity. Smoking was associated with worsening severity of both activity and damage.

Conclusion: CLASI-A and CLASI-D scores can be classified into mild, moderate, and severe categories with high specificity and sensitivity using a large, diverse cohort. This will allow providers to have greater context of disease severity using CLASI scores for prognostic, clinical, and research use. Future studies across multiple cohorts will help validate these ranges.

Reference: 1. Klein R, Moghadam-Kia S, LoMonico J et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011; 147:203-208. doi:10.1001/archdermatol.2010.435

Table 1: Patient Clinical and Demographic Characteristics (N&#3f270)

Table 2: Percent sensitivity, specificity, and correctly classified for CLASI category ranges.

Figure 1: Characteristics associated with different categories of activity and damage.


Disclosures: L. Abbas, None; K. Nandy, None; B. Chong, Daavlin Corporation, 5, Pfizer Incorporated, 12, Site PI for Clinical Trial, Amgen Incorporated, 12, Site PI for Clinical Trial, Biogen Incorporated, 12, Site PI for clinical trial, Viela Bio, 2, Beacon Bioscience, 2, Bristol Meyers Squibb, 1, EMD Serono, 2, Principia Biopharma, 2.

To cite this abstract in AMA style:

Abbas L, Nandy K, Chong B. Classification of Disease Activity and Damage in Cutaneous Lupus [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/classification-of-disease-activity-and-damage-in-cutaneous-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/classification-of-disease-activity-and-damage-in-cutaneous-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology